US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

29.14

+0.43071.50%

Post-market: 29.170.0298+0.10%16:10 EDT

Volume:1K

Turnover:29.61K

Market Cap:2.62M

PE:- -

High:29.31

Open:29.30

Low:29.14

Close:28.71

52wk High:29.31

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:1.28

T/O Rate:1.12%

Dividend:0.92

Dividend Rate:3.15%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

ITC Properties (00199) Establishes AI Infrastructure Business as Separate Reportable Segment

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

Wave Life Sciences initiates Phase 2a combination trial of WVE-007

VOOLT boosts deeptech portfolio with discounted stake in cancer vaccine developer Vaxican

Arterra Bioscience Secures €2 Million Backing for NEX-BIO Biotech Expansion

Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?

Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement

Roche says Phase II obesity study met both primary endpoints

Why Is Moderna Stock (MRNA) Soaring Today, September 21?

William Blair biotech analyst holds an analyst/industry conference call

Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting

Wedbush biotech analyst holds an analyst/industry conference call

Avalyn Pharma announces published results from Phase 1 trials of AP02

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Ultragenyx price target raised to $35 from $32 at Barclays

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NVIB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":29.1392,"timestamp":1790971200000,"preClose":28.7085,"halted":0,"volume":1011,"hourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"delay":0,"changeRate":0.015002525384467948,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.4307,"latestTime":"10-02 16:00:00 EDT","open":29.3,"high":29.31,"low":29.1392,"amount":29609,"amplitude":0.005949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.7085,"nav":29.11,"aum":2619962.27,"dividendRate":0.031511,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"volumeRatio":1.282669145427962},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.282669145427962,"shares":90001,"dividePrice":0.9182,"high":29.31,"amplitude":0.005949,"preClose":28.7085,"low":29.1392,"week52Low":24.54,"pbRate":"--","week52High":29.31,"institutionHeld":0,"latestPrice":29.1392,"eps":0,"divideRate":0.031511,"volume":1011,"delay":0,"ttmEps":0,"open":29.3,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":28.0966,"twentyDayClose":28.4889},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669461761","title":"MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461761","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461761?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:10","pubTimestamp":1790244648,"startTime":"0","endTime":"0","summary":"MediciNova (MNOV) announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicinova-completes-lplv-in-phase-2b-3-clinical-trial-evaluating-mn-166-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicinova-completes-lplv-in-phase-2b-3-clinical-trial-evaluating-mn-166-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNOV","BK4139","MEDX","NVIB","GDOC","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461514","title":"MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461514","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461514?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244000,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368112/7767/en/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-portion-of-the-phase-2b-3-combat-als-trial-of-mn-166-ibudilast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU1988902786.USD","LU0225283273.USD","LU0234570918.USD","LU2089283258.USD","IE00BKVL7J92.USD","EMA","LU1720051017.SGD","LU2264538146.SGD","HYLG","LU2023251221.USD","LU0158827781.USD","LU0912757837.SGD","MNOV","LU1720051108.HKD","LU0882574139.USD","LU2111349929.HKD","LU0795875086.SGD","LU1363072403.SGD","LU0528227936.USD","LU1989772840.SGD","LU1162221912.USD","NVIB","IAI","MEDX","BK4588","ARDS","LU0314104364.USD","BK4504","LU0557290698.USD","LU0106831901.USD","LU0006306889.USD","GDOC","LU1244550577.SGD","IE00B3S45H60.SGD","IDNA","KBWB","LU2357305700.SGD","LU0053666078.USD","LU0106261372.USD","LU0210528500.USD","LU0795875169.SGD","BMED","BK4581","LU1732800096.USD","BK4516","CAFS","LU1244550221.USD","LU0971096721.USD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166586645","title":"ITC Properties (00199) Establishes AI Infrastructure Business as Separate Reportable Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=1166586645","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166586645?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:10","pubTimestamp":1790241040,"startTime":"0","endTime":"0","summary":"ITC Properties (00199) has announced that in September 2026, the company officially changed its name to ITC Neocloud Group Limited.With the development of the group's artificial intelligence (AI)...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXTU","GPTY","GTEK","EPAI","TTEQ","QXQ","RSPT","USMD","AMZD","AMZO","DRAI","QQQG","AIVC","DAT","BTHM","NVIB","TEK","AVGU","00199","THMZ","BK1240","AMZW","SMYY","AVS","TTXU","WDAI","ORCZ","SPRX","ORCS","FXL","TIME","AMZU","AXTX","NTAL","SMCY","AIQD","AVGX","SMCX","QNXT","AXTC","TEKY","MQQQ","WDCC","DARP","FRWD","ORCU","AIS","AVL","AGIQ","AZYY","IVEP","AVGW","QMNV","XQQI","WDCX","BAY","AVGG","AMZZ","AVGC","CRTC","AMZY","ORAC","ORCX","AXTQ","AMAA","AMZP","SMCL","AIPI","INVN","SMCC","SMCZ","FDIF","AMZG","QBIG","QQJG","AXTL","XLKI","ALAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","BK4585","MRNX","IDNA","XLVX","IBB","MEDI","BBP","RSPH","LABU","IYH","TBXU","LFSC","PSCH","BMED","TECB","BK4139","IEIH","GNMX","MESO","BK4588","GDOC","SYNB","MRNY","PINK","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882944","title":"Wave Life Sciences initiates Phase 2a combination trial of WVE-007","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882944?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:35","pubTimestamp":1790163326,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combinatio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","NVIB","HYLG","WVE","GDOC","BK4007","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110098","title":"VOOLT boosts deeptech portfolio with discounted stake in cancer vaccine developer Vaxican","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110098","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110098?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:47","pubTimestamp":1790160467,"startTime":"0","endTime":"0","summary":"An announcement from VOOLT Spolka Akcyjna ( ($PL:VLT) ) is now available. VOOLT S.A. has increased its stake in Polish biotech spin-off Vaxican sp....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-discounted-stake-in-cancer-vaccine-developer-vaxican?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-discounted-stake-in-cancer-vaccine-developer-vaxican?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","EVNT","VLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669556124","title":"Arterra Bioscience Secures €2 Million Backing for NEX-BIO Biotech Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2669556124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669556124?lang=en_us&edition=fundamental","pubTime":"2026-09-23 03:02","pubTimestamp":1790103749,"startTime":"0","endTime":"0","summary":"The latest update is out from Arterra Bioscience SpA ( ($IT:ARBS) ). Arterra Bioscience S.p.A., a Naples-based green biotech group listed on Eurone...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arterra-bioscience-secures-e2-million-backing-for-nex-bio-biotech-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arterra-bioscience-secures-e2-million-backing-for-nex-bio-biotech-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IOBT","BK4588","BK4585","BK4139","VGT","XBI","XBIX","NVIB","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669610140","title":"Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669610140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669610140?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:58","pubTimestamp":1790085506,"startTime":"0","endTime":"0","summary":"Viking Therapeutics stock rallied more than 32% on Tuesday following a clinical trial update for weight loss drug VK2735.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4585","BK4139","BK4588","HYLG","VKTX","MEDX","BK4599","GDOC","OZEM","THNR","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669739142","title":"Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669739142","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669739142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (\"Optimi\" or the \"Company\"), a commercial-stage pharmaceutical manufacturer of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPTH","GDOC","NVIB","HYLG","MEDX","IDNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669314478","title":"Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669314478","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669314478?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:27","pubTimestamp":1790080047,"startTime":"0","endTime":"0","summary":"An announcement from Enlivex ( ($ENLV) ) is now available. Enlivex Ltd., a Nasdaq-listed longevity-focused biotech, is developing Allocetra™, an ad...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enlivex-drops-rain-token-financing-deal-halts-planned-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enlivex-drops-rain-token-financing-deal-halts-planned-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","LCLG","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414868","title":"Roche says Phase II obesity study met both primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414868?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:20","pubTimestamp":1790068829,"startTime":"0","endTime":"0","summary":"Roch announced topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide, an investigational, once-weekly dual GLP-1/GIP re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","JDOC","GDOC","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160402","title":"Why Is Moderna Stock (MRNA) Soaring Today, September 21?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160402?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:54","pubTimestamp":1790016874,"startTime":"0","endTime":"0","summary":"Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","BK4501","BK4534","NVIB","BK4568","BK4551","WDNA","IDNA","BK4532","BK4533","MRNY","BK4585","BK4139","XBIX","LGHT","BK4588","GNOM","MRNA","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669253162","title":"William Blair biotech analyst holds an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669253162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669253162?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:35","pubTimestamp":1790008535,"startTime":"0","endTime":"0","summary":"Biotech Analyst Minter, along with Ross Summer, MD, discuss updates in idiopathic pulmonary fibrosis ahead of IPF summit conference and expected AL...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/william-blair-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/william-blair-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","XBIX","BK4581","BK4585","BK4588","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164926","title":"Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164926","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164926?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:32","pubTimestamp":1790004777,"startTime":"0","endTime":"0","summary":"Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB, a Stockholm-listed biotech focused on hard-to-treat cancers, is using its p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncopeptides-to-present-new-pepaxti-data-at-key-myeloma-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncopeptides-to-present-new-pepaxti-data-at-key-myeloma-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0516422366.SGD","LU0048573645.USD","LU0345776255.USD","LU1861217088.USD","IE0001KFT4U8.USD","LU0516423091.SGD","BK4585","LU1242518857.USD","LU0289960550.SGD","LU0499858438.USD","LU2360107671.USD","SG9999014492.USD","BK4588","SG9999014484.SGD","SGXZ58947870.SGD","BK4566","LU0251143029.SGD","LU0572939691.SGD","NVIB","LU1048588211.SGD","LU2238330802.EUR","SG9999001135.SGD","BK4220","BK4551","BK4548","LU2065171311.SGD","LU2125910500.SGD","XBIX","BK4535","SE","LU0532188223.SGD","LU0823038988.USD","LU2065170008.USD","SG9999013460.SGD","LU1861220207.SGD","LU2152927971.USD","LU0737861269.HKD","LU0516422440.USD","IE00BD6J9T35.USD","LU2543165471.USD","LU2177674079.SGD","LU0516423174.USD","LU1839390173.USD","SG9999002679.SGD","FDNI","LU1770036033.HKD","LU1242518931.SGD","LU0175139822.USD","LU0210637038.USD","LU0572940350.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110169","title":"Wedbush biotech analyst holds an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110169","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110169?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:55","pubTimestamp":1789998926,"startTime":"0","endTime":"0","summary":"Biotech Analyst Zhong, along with Philip J. Mease, MD, of the University of Washington School of Medicine, discuss the positioning of emerging IL-1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wedbush-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wedbush-biotech-analyst-holds-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","XBIX","BK4588","NVIB","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669661341","title":"Avalyn Pharma announces published results from Phase 1 trials of AP02","url":"https://stock-news.laohu8.com/highlight/detail?id=2669661341","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669661341?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:10","pubTimestamp":1789996248,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","MEDX","NVIB","BMED","HYLG","BBC","AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316610","title":"InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316610","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316610?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995600,"startTime":"0","endTime":"0","summary":"- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365503/0/en/inspiremd-announces-amendments-to-certain-series-j-and-series-k-warrants-providing-potential-gross-proceeds-of-up-to-11-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","MRNY","LFSC","PSCH","IEIH","SYNB","MEDI","GNMX","RSPH","MRNX","PINK","NSPR","BMED","BK4585","BBP","BK4588","IBB","NVIB","TBXU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","PINK","BK4139","PSCH","MRNX","MRNY","IBB","TECB","RSPH","BK4588","GDOC","SYNB","IEIH","BMED","GNMX","MEDI","BK4585","IDNA","BBP","IYH","TBXU","FRTY","RARE","LABU","NVIB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668318487","title":"Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668318487","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668318487?lang=en_us&edition=fundamental","pubTime":"2026-09-20 22:15","pubTimestamp":1789913705,"startTime":"0","endTime":"0","summary":"Cue Biopharma (CUE) announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IDNA","PSIL","NVIB","BBC","CUE","HYLG","MEDX","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668186624","title":"Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2668186624","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668186624?lang=en_us&edition=fundamental","pubTime":"2026-09-20 18:00","pubTimestamp":1789898400,"startTime":"0","endTime":"0","summary":"Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/20/3365072/0/en/cue-biopharma-announces-positive-topline-results-from-cue-221-phase-2-study-in-chronic-spontaneous-urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","IDNA","MEDX","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}